A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

97 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation

NCT00741936

Functional Gastrointestinal Disorders Constipation

COMPLETED PHASE2

Clinical Trial on Palliative Cancer Patients With Constipation

NCT02795390

Constipation

COMPLETED PHASE2

Cross Sectional Study of Constipation in Advanced Cancer Patients

NCT01399294

Palliative Care Constipation Traditional Chinese Medicine

COMPLETED

Effect of Chinese Herb on Chronic Constipation for Residents in Long-Term Care Units

NCT00354575

Chronic Constipation

COMPLETED PHASE2

Fecal Microbiota Transplantation for Chronic Functional Constipation

NCT03018613

Chronic Functional Constipation Intestinal Bacteria Flora Disturbance Fecal Microbiota Transplantation

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.

Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.

Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.

Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".

It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MaZiRenWan (MZRW) Low dose

MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks

Group Type EXPERIMENTAL

MaZiRenWan (MZRW) Low dose

Intervention Type DRUG

Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

MaZiRenWan (MZRW) Median dose

MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks

Group Type EXPERIMENTAL

MaZiRenWan (MZRW) Median dose

Intervention Type DRUG

Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

MaZiRenWan (MZRW) High dose

MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks

Group Type EXPERIMENTAL

MaZiRenWan (MZRW) High dose

Intervention Type DRUG

Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MaZiRenWan (MZRW) Low dose

Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

Intervention Type DRUG

MaZiRenWan (MZRW) Median dose

Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

Intervention Type DRUG

MaZiRenWan (MZRW) High dose

Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hemp Seed Pill Hemp Seed Pill Hemp Seed Pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of functional constipation with Rome II criteria
* General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
* Complete spontaneous bowel movement≦2 movements per week

Exclusion Criteria

* Anti-diarrhoeal therapy
* Drug-induced constipation
* Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
* Medical history of previous abdominal surgery
* Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
* Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
* History of laxative abuse
* History of allergy to Chinese herbal medicine
* Psychiatric or addictive disorders
* Pregnancy or breast-feeding
* Any other serious diseases

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No